Trastuzumab/chemotherapy combinations in metastatic breast cancer

被引：58

作者：

Ligibel, JA

Winer, EP

机构：

[1] Dana Farber Canc Inst, Boston, MA 02115 USA

[2] Harvard Univ, Sch Med, Boston, MA USA

[3] Brigham & Womens Hosp, Boston, MA 02115 USA

来源：

SEMINARS IN ONCOLOGY | 2002年 / 29卷 / 03期

关键词：

D O I：

10.1053/sonc.2002.34054

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：38 / 43

页数：6

共 48 条

[1]

Baselga J, 1997, Oncology (Williston Park), V11, P43

[2] Phase II study of weekly intravenous recombinant humanized Anti-p185(HER2) monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast [J].

Baselga, J ;

Tripathy, D ;

Mendelsohn, J ;

Baughman, S ;

Benz, CC ;

Dantis, L ;

Sklarin, NT ;

Seidman, AD ;

Hudis, CA ;

Moore, J ;

Rosen, PP ;

Twaddell, T ;

Henderson, IC ;

Norton, L .

JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (03) :737-744

[3]

Baselga J, 1998, CANCER RES, V58, P2825

[4] Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer [J].

Batist, G ;

Ramakrishnan, G ;

Rao, CS ;

Chandrasekharan, A ;

Gutheil, J ;

Guthrie, T ;

Shah, P ;

Khojasteh, A ;

Nair, MK ;

Hoelzer, K ;

Tkaczuk, K ;

Park, YC ;

Lee, LW .

JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (05) :1444-1454

[5]

BIANCO AR, 2000, P 36 ANN M AM SOC CL, V19, P75

[6] Docetaxel (Taxotere) plus trastuzumab (Herceptin) in breast cancer [J].

Burris, HA .

SEMINARS IN ONCOLOGY, 2001, 28 (01) :38-44

[7] Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer [J].

Burstein, HJ ;

Kuter, I ;

Campos, SM ;

Gelman, RS ;

Tribou, L ;

Parker, LM ;

Manola, J ;

Younger, J ;

Matulonis, U ;

Bunnell, CA ;

Partridge, AH ;

Richardson, PG ;

Clarke, K ;

Shulman, LN ;

Winer, EP .

JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (10) :2722-2730

[8] Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer [J].

Chan, S ;

Friedrichs, K ;

Noel, D ;

Pintér, T ;

Van Belle, S ;

Vorobiof, D ;

Duarte, R ;

Gil, MG ;

Bodrogi, I ;

Murray, E ;

Yelle, L ;

von Minckwitz, G ;

Korec, S ;

Simmonds, P ;

Buzzi, F ;

Mancha, RG ;

Richardson, G ;

Walpole, E ;

Ronzoni, M ;

Murawsky, M ;

Alakl, M ;

Riva, A ;

Crown, J .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (08) :2341-2354

[9]

CHAZIN VR, 1992, ONCOGENE, V7, P1859

[10] Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease [J].

Cobleigh, MA ;

Vogel, CL ;

Tripathy, D ;

Robert, NJ ;

Scholl, S ;

Fehrenbacher, L ;

Wolter, JM ;

Paton, V ;

Shak, S ;

Lieberman, G ;

Slamon, DJ .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (09) :2639-2648

← 1 2 3 4 5 →